Robert Hartman Md

CLIA Laboratory Citation Details

2
Total Citations
5
Total Deficiencyies
5
Unique D-Tags
CMS Certification Number 05D0560613
Address 5400 Balboa Blvd, Ste 329, Encino, CA, 91316-1502
City Encino
State CA
Zip Code91316-1502
Phone818 907-7076
Lab DirectorROBERT HARTMAN

Citation History (2 surveys)

Survey - April 17, 2025

Survey Type: Standard

Survey Event ID: UOYO11

Deficiency Tags: D3011 D5217 D6082

Summary:

Summary Statement of Deficiencies D3011 FACILITIES CFR(s): 493.1101(d) Safety procedures must be established, accessible, and observed to ensure protection from physical, chemical, biochemical, and electrical hazards, and biohazardous materials. This STANDARD is not met as evidenced by: Based on the surveyor's review of the laboratory's policy and procedure binder, observations during the tour, and an interview with the administration manger (AM), it was determined that the laboratory failed to establish safety procedures to ensure protection from physical, chemical, biochemical, and biohazardous materials. The findings include: 1. The laboratory lacked an established safety policy and procedure to provide protection from physical, chemical, biochemical, and biohazardous materials as needed. 2. The laboratory did not have an eye wash station or a portable eye wash bottle in place, as observed and noted by the surveyor during the facility tour. 3. The AM affirmed by interview on April 17, 2025 at approximately 3:50 p.m., that the laboratory lacked a safety policy and procedure, as well as an eye wash in the laboratory area. 4. The safety of laboratory personnel could not be assured. 5. The annual testing declaration form (Lab-144) signed by the director on April 14, 2025, stated that the laboratory processed approximately 1,214 patient tests for Mycology, Parasitology, and Dermatopathology during the time when neither a safety protocol nor an eye wash station/bottle was in place. D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- This STANDARD is not met as evidenced by: Based on the surveyor's review of the laboratory's policy and procedure, peer review records, five (5) randomly selected patient records, and an interview with the administration manager (AM); it was determined that the laboratory failed to verify the accuracy of any test or procedure performed at least twice annually for the years 2022, 2023, and 2024. The findings include: 1. The laboratory's policies and procedures for proficiency testing stated that cases are sent to another facility to verify the accuracy of results for Dermatopathology. However, no records for the years 2022, 2023, and 2024 were found to have met the 493.1236(c) standard regulation. Therefore, the accuracy of patient results could not be assured. 2. Review of the laboratory's proficiency testing protocol for Mycology and Parasitology indicated that the laboratory director (LD) will attend the assessment class at San Fernando Valley Dermatological Society. However, no documentation found for the years 2022, 2023, and 2024. 3. The AM affirmed by interview on April 17, 2025, at approximately 2:35 p.m., that the laboratory missed to perform proficiency testing as mentioned in statements #1 and #2. 4. The laboratory's testing declaration form submitted at the time of the survey stated that 1,214 tests in Mycology, Parasitology, and Dermatopathology are performed annually during the time that no proficiency testing that met the CLIA requirements were performed. D6082 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(1) (e) The laboratory director must-- (e)(1) Ensure that testing systems developed and used for each of the tests performed in the laboratory provide quality laboratory services for all aspects of test performance, which includes the preanalytic, analytic, and postanalytic phases of testing; This STANDARD is not met as evidenced by: Based on the surveyor's review of the laboratory's policies and procedures, randomly selected patient test records, observations during the tour of the facility, and an interview with the administration manager (AM) on April 17, 2025, the laboratory director is herein cited due to failure to ensure that several aspects of the preanalytic, analytical, and postanalytic phases of the laboratory testing were monitored. The findings include: 1. Lack of safety procedures and measures. See D3011. 2. Lack of proficiency testing for the years 2022, 2023, and 2024. See D5217. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 22, 2018

Survey Type: Standard

Survey Event ID: BH1H11

Deficiency Tags: D5779 D5203

Summary:

Summary Statement of Deficiencies D5203 SPECIMEN IDENTIFICATION AND INTEGRITY CFR(s): 493.1232 The laboratory must establish and follow written policies and procedures that ensure positive identification and optimum integrity of a patient's specimen from the time of collection or receipt of the specimen through completion of testing and reporting of results. This STANDARD is not met as evidenced by: Based on review of a patient chart, doctor's order and a final report of a biopsy taken on 12/2/2016, the laboratory failed to establish and follow written policy and procedure to ensure that a positive identification of patient's specimen from the time of collection or receipt of the specimen through completion of testing and reporting of results. The findings included: a. On 12/2/2016, patient (A) had an order of a Biopsy by Shave method and destruction from two (2) locations, Location A: Left Ear, Location B: Left Cheek. The two locations were supported by a Biopsy map marked by the respective locations. b. The biopsy results were described from different anatomic sites. The report was signed by the Laboratory Director dated on 12/12 /2016, Diagnosis: "A) Skin (Right ear, excision): Nodular Basal Cell Carcinoma B) Skin (Left Chest, Excision): Nodular Basal Cell Carcinoma" c. The anatomic sites described on the patient's plan and the description on the patient's Pathology reports revealed discrepancies. There was no documentation of

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access